Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis
- PMID: 18456465
- DOI: 10.1016/j.ijantimicag.2008.01.027
Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis
Abstract
As high drug levels at the infection site are desirable for optimal activity, this study explored whether one dose of azithromycin extended release (AZ-ER) achieved higher azithromycin exposure in sinus fluid than azithromycin immediate release (AZ-IR) in adults with acute bacterial sinusitis. Subjects received AZ-ER (2g single dose; n=5) or AZ-IR (500mg daily for 3 days; n=4) and blood and sinus aspirates were collected until 120 h after initial dosing. Within 24 h, exposure was four- and three-fold higher with AZ-ER than with AZ-IR in serum and sinus fluid, respectively. Sinus fluid exposure was five- and three-fold higher than serum for AZ-IR and AZ-ER, respectively. Azithromycin concentrations in sinus fluid were maintained up to 120 h.
Similar articles
-
Pharmacokinetics of azithromycin in plasma and sinus mucosal tissue following administration of extended-release or immediate-release formulations in adult patients with chronic rhinosinusitis.Int J Antimicrob Agents. 2009 Jul;34(1):67-71. doi: 10.1016/j.ijantimicag.2009.01.014. Int J Antimicrob Agents. 2009. PMID: 19307106 Clinical Trial.
-
Onset of symptom resolution in adults with acute bacterial rhinosinusitis treated with a single dose of azithromycin extended release compared with 10 days of levofloxacin: a retrospective analysis of a randomized, double-blind, double-dummy trial.Clin Ther. 2007 Dec;29(12):2690-8. doi: 10.1016/j.clinthera.2007.12.030. Clin Ther. 2007. PMID: 18201585
-
Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin.J Antimicrob Chemother. 2008 Apr;61(4):884-91. doi: 10.1093/jac/dkn032. Epub 2008 Feb 4. J Antimicrob Chemother. 2008. PMID: 18252692 Clinical Trial.
-
Azithromycin extended-release (Zmax) for sinusitis and pneumonia.Obstet Gynecol. 2006 Jan;107(1):180-2. doi: 10.1097/01.AOG.0000195219.71794.16. Obstet Gynecol. 2006. PMID: 16394059 Review. No abstract available.
-
Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.Drugs. 2007;67(5):773-92. doi: 10.2165/00003495-200767050-00010. Drugs. 2007. PMID: 17385947 Review.
Cited by
-
Bioequivalence of 2 azithromycin capsule formulations: a randomized, single-dose, open-label, 2-period crossover study in healthy male pakistani volunteers.Curr Ther Res Clin Exp. 2011 Jun;72(3):95-108. doi: 10.1016/j.curtheres.2011.04.001. Curr Ther Res Clin Exp. 2011. PMID: 24648579 Free PMC article.
-
Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age.Antimicrob Agents Chemother. 2012 Feb;56(2):715-24. doi: 10.1128/AAC.00717-11. Epub 2011 Nov 21. Antimicrob Agents Chemother. 2012. PMID: 22106226 Free PMC article. Clinical Trial.
-
Is there a role for antibiotics in the treatment of chronic rhinosinusitis?J Allergy Clin Immunol. 2022 May;149(5):1504-1512. doi: 10.1016/j.jaci.2022.02.004. Epub 2022 Feb 22. J Allergy Clin Immunol. 2022. PMID: 35217148 Free PMC article. Review.
-
The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP).Curr Allergy Asthma Rep. 2017 May;17(5):30. doi: 10.1007/s11882-017-0696-z. Curr Allergy Asthma Rep. 2017. PMID: 28429305 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials